Position:Senior Medical Statistician
Dr Olorunsola (Shola) Agbaje is a Senior Medical Statistician at the University of Oxford Diabetes Trials Unit (DTU). He joined the DTU in March 2013 where he serves as the statistical lead in the Translational Research Group (TRG) and the Oxford statistical lead for the MASTERMIND study.
Prior to joining the DTU, he was a Senior Medical Statistician in the Department of Research Oncology at Guy’s Hospital, London. At Guy’s, he provided statistical expertise and leadership for various research teams, with a particular focus on clinical trials for the evaluation of surgical devices for breast cancer surgeries and modelling prediction of breast cancer survival using clinical, biochemical and gene expression data.
Shola was a member of the Metabolic Modelling Group at the University of Cambridge. During this time, he worked on a number of glucose control projects, CLINICIL for monitoring blood glucose for critically ill patients, artificial pancreas for the treatment of subjects with type I diabetes and a number of advanced statistical models for estimating insulin sensitivity and glucose effectiveness in type II diabetes.
Research interests have focused mainly on advanced statistical modelling techniques and their medical applications, with particular interests in design and analysis of clinical experiments, statistical models for intensive longitudinal data and event history analysis.
Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients
Chitrabhanu Ballav et al.
Endocrinol Diab Metab. 2020
Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)
Ernesto Maddaloni et al.
Lancet Diabetes Endocrinol 2020;8:206-15
Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates
Mostafa SA et al.
J Diabetes Complications 2019;33:69-74
The effect of lixisenatide on post-prandial blood glucose and glucagon in type 1 diabetes
C. Ballav et al.
Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
S. A. Mostafa et al.
Diabet Med. 2018;35:72-77
Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
O.F. Agbaje et al.